Martin Schuler

发表

Drupal-basierte Infrastruktur zur Vermittlung von Fachterminologie. Das Konzept für ein zweisprachiges Fachwörterbuch in der Mediencommunity

Ilona Buchem, Anne König, Thomas Hagenhofer, 2010, Mensch & Computer Workshopband.

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Dejan Juric, Jordi Rodon, Alan Huang, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer

Dirk Hasenclever, Jan G Hengstler, Susanne Gebhard, 2008, Clinical Cancer Research.

Targeted therapies in gastroesophageal cancer.

Martin Schuler, M. Schuler, S. Kasper, 2014, European journal of cancer.

Cytochrome C Maintains Mitochondrial Transmembrane Potential and Atp Generation after Outer Mitochondrial Membrane Permeabilization during the Apoptotic Process

Martin Schuler, Oliver von Ahsen, D. Green, 2001, The Journal of cell biology.

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

Birgit Gaschler-Markefski, Martin Schuler, Holger Fritsch, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

Michael Thomas, Armando Santoro, Martin Schuler, 2016, The Lancet. Oncology.

Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level

Klaus Gerwert, Ibrahim Daho, Samir F El-Mashtoly, 2018, Scientific Reports.

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

Jan G. Hengstler, Wiebke Schormann, Katja Ickstadt, 2011, Breast Cancer Research and Treatment.

Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.

David M. Hyman, Vivek Subbiah, Jean-Yves Blay, 2017 .

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Manuel Hidalgo, Martin Schuler, Fabrice Andre, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort

Bastien Cabarrou, Thomas Filleron, Juergen Wolf, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive genomic profiles of small cell lung cancer

Martin Vingron, Jan O. Korbel, Lucia Anna Muscarella, 2015, Nature.

Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients

Martin Eisenacher, Maike Ahrens, Stefan Welter, 2016, Journal of Cancer Research and Clinical Oncology.

Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis

Martin Schuler, Jerry E. Chipuk, T. Kuwana, 2004, Science.